Mesoblast is a global leader in the field of regenerative medicine. We have established what we believe is the industry’s most clinically advanced and diverse portfolio of regenerative therapeutic cell-based products. We have five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. All our clinical programs target therapeutic areas with significant, unmet medical needs including cardiac diseases, immune-mediated and inflammatory conditions, oncology and hematology diseases, and spine orthopedic disorders.
Our proprietary technology platform is based on mesenchymal lineage adult stem cells (MLCs) and underpins all our therapeutic products. Our lead product candidates include MPC-150-IM for congestive heart failure, MPC-06-ID for chronic lower back pain due to moderate degenerative disc disease, MSC-100-IV for steroid refractory acute graft versus host disease (GVHD), and MPC-300-IV for biologic refractory rheumatoid arthritis, and diabetic nephropathy.
All our products are allogenic or “off-the-shelf”, meaning stem cells from a young, healthy adult donor can be expanded and used in many unrelated patients without the need for tissue matching. Our proprietary manufacturing processes are designed to enable production at commercial scale with reproducibility and batch-to-batch consistency.
Our portfolio of MLC-derived product candidates each has its own distinct technical characteristics, target indications, individual reimbursement strategy, separate commercialization potential, and unique partnering opportunities.
Our products have been prioritized into two tiers. Tier 1 represents our lead programs where we focus the majority of our time and resources. Tier 2 programs have the potential to advance to Tier 1 depending on newly-generated data, market opportunity or partnering options. Additionally, we have a significant pipeline of earlier-stage programs.
We have established strategic relationships with several industry leaders to support clinical development, manufacturing and commercial capabilities. Our partners include Teva Pharmaceutical Industries Ltd, JCR Pharmaceuticals Co. Ltd and Lonza.
With a strong patent portfolio of 67 patent families, we believe we have substantial competitive advantages for the commercial development of regenerative medicine products.
Led by Chief Executive Silviu Itescu, a pioneer of stem cell therapeutics, the Mesoblast management team has substantial experience in all aspects of biopharmaceutical development. There are approximately 120 employees, primarily in the USA, and in Australia and Singapore.
Mesoblast was publicly listed on the Australian Securities Exchange (ASX:MSB) in 2004. The Company has a Level 1 American Depositary Receipt (ADR) program facility trading in the Over-The-Counter (OTC) market in the United States. Mesoblast ADRs trade under the symbol of MBLTY.